CJC-1295 Side Effects: Trials, FDA Record, No-DAC

CJC-1295 Side Effects: The Short Answer

Which CJC-1295 you mean decides the answer, and the version with human data is not the version you will be prescribed. Every published trial used CJC-1295 with DAC, the once-weekly molecule: injection-site reactions first, then headache, flushing, nausea, diarrhea, brief dizziness with low blood pressure, and a faster heart rate, none classed as serious. The no-DAC form, Modified GRF 1-29, goes into CJC-1295/Ipamorelin Explore PeRxCJC-1295/IpamorelinPulsatile Growth Hormone ReleaseView peptide blends, ours included, and has never had a human safety trial. The complete CJC-1295/Ipamorelin guide Read nextCJC-1295 Ipamorelin: The Complete GuideCJC-1295 Ipamorelin pairs a GHRH signal that primes growth hormone release with a clean pulse trigger that fires it. After age 30, your body produces roughly 15% less growth hormone every decade. This stack doesn't replace what you've lost with synthetic hormones. It tells your body to start making more of its own again. Together, the two peptides form the most popular growth hormone optimization protocol in peptide therapy.Read article covers what the blend is for; this page covers only what can go wrong.

What the DAC-Form Human Studies Recorded

Two papers from 2006 hold the entire published human safety record. Teichman and colleagues ran two randomized, double-blind, placebo-controlled studies in healthy adults aged 21 to 61: single ascending doses in one, two or three weekly or biweekly doses in the other, over 28 and 49 days. The abstract reports no serious adverse reactions and calls the drug relatively well tolerated.

The adverse event detail never reached the abstract. FDA staff read it out for the December 2024 advisory committee: in the single-dose study 94 percent of subjects reported an adverse event, injection-site reactions occurred in about 70 percent of those given the drug and rarely on placebo, reactions were more severe or prolonged at higher doses, and headache, diarrhea and systemic vasodilatory reactions were also observed. In the repeat-dose study every subject on active drug had an injection-site reaction, plus flushing, headache, nausea, abdominal pain, transient involuntary leg muscle contractions with some loss of coordination, and transient dizziness with low blood pressure.

Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. PMID 16352683. DAC form. View study

Ionescu and Frohman sampled blood every 20 minutes overnight in healthy men aged 20 to 40, before and one week after a single DAC injection. Pulse frequency and size were unchanged; the trough between pulses rose 7.5-fold, mean GH 46 percent and IGF-1 45 percent. DAC raises the floor rather than flattening the pattern. The FDA summary adds increased heart rate and transient redness and tenderness at the site.

Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. PMID 17018654. DAC form, single dose. View study

ConjuChem took the DAC form into a Phase 2 trial in people with HIV-associated lipodystrophy, weekly injections over twelve weeks. By the FDA account, assembled from anecdotal reports, one participant developed chest discomfort two hours after an eleventh weekly dose, an ECG confirmed an acute myocardial infarction, and the participant died about an hour later. The attending physician judged symptom-free coronary artery disease with a ruptured plaque the most likely cause. The trial was terminated, the data were never published, and ConjuChem withdrew the DAC form from trials that year. Whether the drug contributed is unknown (CJC-1295 guide Read nextCJC-1295 Peptide: What It Is, DAC vs No DACCJC-1295 is a lab-made version of the hormone that tells your pituitary to release growth hormone. The complication is that two different molecules are sold under that one name, one built to last a week and one built to clear quickly, and almost every published human result belongs to only one of them. This guide sorts out which is which, what the evidence covers, and why we had to pick a side.Read article ).

US Food and Drug Administration, Pharmacy Compounding Advisory Committee. Meeting transcript, Topic 1: CJC-1295-related bulk drug substances. December 4, 2024. Source for the adverse event summary and the Phase 2 account. View study

CJC-1295 DAC Side Effects vs No-DAC

If you searched for CJC-1295 DAC side effects, the list above is the direct answer, and it is what stands behind the FDA statement that it has identified serious adverse events with CJC-1295, including increased heart rate and systemic vasodilatory reaction. We do not prescribe that form. The no-DAC form has no list because nobody has studied it; what follows is pharmacology plus prescribing experience.

Lower exposure and a short tail are why we expect fewer fluid and injection-site problems, and why a bad night can be followed by a night off. The same logic cuts the other way: a form with no trial has a thinner margin for anything unmeasured, and the FDA flags immune reactions for both (why we pair CJC-1295 with ipamorelin Read nextWhy We Pair CJC-1295 With Ipamorelin (No-DAC)CJC-1295 and Ipamorelin act on two different receptors, so together they produce a bigger, cleaner growth-hormone pulse than either one alone. The detail most people miss: we use the no-DAC version of CJC-1295 on purpose. That choice is what keeps the release pulsatile and physiologic instead of a flat, all-day elevation. Here is the reasoning behind the pairing.Read article ).

CJC-1295/Ipamorelin

The vial carries part of the risk: an unknown form, a guessed concentration, impurities that provoke immune reactions. PeRx CJC-1295/Ipamorelin is the no-DAC form, labeled as such, compounded by a state-licensed 503A pharmacy at a fixed concentration, and it ships fully reconstituted and ready to use.

$299 for a one-month supply, syringes and swabs included, prescribed only after a licensed provider reviews your history.

The no-DAC form, labeled as such.

View CJC-1295/Ipamorelin

What the FDA Has Said, by Date

Neither form of CJC-1295 is an FDA-approved drug, for any use. The record below is stated as of November 2026 and may move again.

The votes are advisory, the agency has finalized nothing in either direction, and the vial a patient receives is a compounded drug from a state-licensed 503A pharmacy on an individual prescription, with no FDA review of its safety, effectiveness or quality. More in is CJC-1295/Ipamorelin FDA approved Read nextIs CJC-1295/Ipamorelin FDA Approved? (2026 Answer)The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.Read article , FDA-approved peptides Read nextFDA-Approved Peptides: The Full List (2026)Peptide drugs have been FDA-approved for over forty years, from recombinant insulin in 1982 to tirzepatide in 2022. Most of the peptides people actually search for, though, are not on that list. This guide lays out every FDA-approved peptide drug with its brand names and approval year, explains the difference between an approved drug, a compounded medication, and a research chemical, and covers where the 2026 FDA compounding review left peptides like BPC-157. Current as of August 2026.Read article and the July 2026 FDA review Read nextJuly 2026 FDA Peptide Panel: BPC-157 ReviewOn July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides, including BPC-157, TB-500, and Semax. Despite the headlines, this is not a ban, and these peptides are not suddenly "legal again" either. Here is the precise, physician-reviewed picture of where things actually stand and what it means if you use peptide therapy.Read article .

US Food and Drug Administration. "Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024." Votes on the five CJC-1295-related substances. View study

US Food and Drug Administration. "Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024." Votes on ipamorelin (free base) and ipamorelin acetate. View study

US Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." Current as of April 22, 2026. CJC-1295 entry among withdrawn nominations. View study

US Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Updated May 14, 2026. View study

The First Two Weeks on the Blend: Hunger, Dreams, Water

The PeRx prescription is one vial of the no-DAC form blended with ipamorelin; the concentration is printed on the label and the prescribed dose arrives on paper with it. The instructions say to inject at bedtime, Monday through Friday, on an empty stomach at least two hours after the last meal, not to eat afterward, and to stop for one month after three months of use. They also say what to expect: "You may notice increased hunger, vivid dreams, or mild water retention in the first few days; this is normal and typically settles." The arithmetic behind the dose lives on the dosage chart Read nextCJC-1295/Ipamorelin Dosage Chart: Units & TimingMost CJC-1295 ipamorelin dosage advice online is written in milligrams for a different molecule, or assumes you are juggling two separate vials. PeRx ships one combined vial at a fixed concentration, ready to use. This page converts insulin-syringe units into micrograms of each peptide at that concentration, explains the bedtime and empty-stomach rules, walks through 5-on-2-off and 3-months-on cycling, and prices out a month, as of August 31, 2026.Read article . The three expected effects are patient reports, not trial counts. Ipamorelin brings its own list, covered in the ipamorelin guide Read nextIpamorelin Peptide: What It Does, Doses, EvidenceIpamorelin is a five-amino-acid peptide that tells the pituitary to release a pulse of growth hormone. Its reputation rests on one word, selective, and that word traces back to a 1998 experiment in pigs. The human record is narrower than most pages admit: one dosing study by IV infusion and a surgical program that failed. This guide covers what ipamorelin does, where the dose numbers online come from, what FDA reviewers concluded in 2024, and why we only prescribe it paired.Read article .

Hunger. Ipamorelin is a ghrelin-receptor agonist, and ghrelin is the hunger hormone. Whether ipamorelin itself raises appetite in people has never been measured; the closest evidence is a related agonist, GHRP-2, which increased buffet-meal intake by about 36 percent in seven lean, healthy men. The pig study clinics cite for its selectivity did not measure appetite. Expect some hunger in the first week, and do not eat after the dose: food blunts the pulse it exists to create.

Laferrère B, Abraham C, Russell CD, Bowers CY. "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men." Journal of Clinical Endocrinology and Metabolism. 2005;90(2):611-614. PMID 15699539. GHRP-2, not ipamorelin. View study

Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PMID 9849822. Animal study; appetite not measured. View study

Vivid dreams and heavier sleep. GHRH itself promotes sleep: in healthy young men, an intravenous dose increased REM sleep when given early in the night and sharply increased slow-wave sleep when given late. That was natural GHRH by vein, but it is the likeliest root of the vivid dreams and heavy first nights patients describe. Dream vividness has not been measured with either form; it usually fades within two weeks.

Kerkhofs M, Van Cauter E, Van Onderbergen A, et al. "Sleep-promoting effects of growth hormone-releasing hormone in normal men." American Journal of Physiology. 1993;264(4 Pt 1):E594-E598. PMID 8476038. Natural GHRH, intravenous. View study

Water retention. Growth hormone shifts fluid balance, so a pound or two on the scale, puffy fingers or a tighter ring in the first week is the usual shape of it. With one pulse a night it tends to stay mild and settle by week three or four. The injection site itself should show no more than a small pink patch or a sting that fades within hours; rotate sites from the first night (where to inject CJC-1295/Ipamorelin Read nextWhere to Inject CJC-1295/Ipamorelin: Sites, TimingCJC-1295/Ipamorelin is a single subcutaneous injection, and for this stack the two decisions that matter most are where you put it and when. The four standard sites all work, but bedtime timing and an empty stomach change the result more than site choice does. Here is the practical guide patients ask for after their first vial arrives.Read article ).

Joints, Hands and Fluid: The Growth Hormone Effects to Watch

Fluid retention, joint pain, carpal tunnel symptoms and gynecomastia appear on nearly every CJC-1295 side-effect list, and none was reported in the CJC-1295 trials. A 2007 systematic review in the Annals of Internal Medicine pooled randomized trials of injected growth hormone in healthy older adults, 220 people treated for an average of 27 weeks: significantly more soft tissue swelling, joint pain, carpal tunnel syndrome and gynecomastia, somewhat more diabetes and impaired fasting glucose, and no change in weight.

Liu H, Bravata DM, Olkin I, et al. "Systematic review: the safety and efficacy of growth hormone in the healthy elderly." Annals of Internal Medicine. 2007;146(2):104-115. PMID 17227934. Injected growth hormone, not CJC-1295. View study

A GHRH analog works upstream: the pituitary answers within its own limits, somatostatin still cuts release off, and the no-DAC request lasts one pulse. That is reasoning, not measurement, and FDA reviewers made the opposite point just as fairly: nothing shows the risks printed on approved growth hormone labels are absent with CJC-1295. Watch for swelling that keeps building, joint pain beyond a dull ache, and numbness or tingling in the hands.

Blood Sugar and Insulin

Growth hormone counters insulin. It raises free fatty acids and pushes liver and muscle toward insulin resistance; people with growth hormone deficiency become temporarily more insulin resistant when treatment starts. A 2009 review in Endocrine Reviews lays out the human data.

Møller N, Jørgensen JO. "Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects." Endocrine Reviews. 2009;30(2):152-177. PMID 19240267. View study

The CJC-1295 trials reported no blood sugar changes, and as short hormone studies in healthy adults they were not built to find one. The injected growth hormone trials did. A bedtime pulse lands during the overnight fast, so the plausible effect is a nudge toward higher fasting glucose, not a crash. Diabetes and prediabetes go on the intake form and weigh against prescribing until glucose is stable; glucose-lowering drugs go on the same form, since no interaction study exists; PeRx does not order labs; the check-in before each renewal asks about symptoms. If you have your own doctor, a fasting glucose, HbA1c and IGF-1 before you start and a few months in are worth asking for (lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article , peptide safety monitoring Read nextPeptide Safety Monitoring: Signals During TherapyThe most important safety tool on peptide therapy is your own attention. Most peptides are well tolerated, and the side effects people do notice are usually mild and easy to read once you know what is normal, what is worth mentioning, and what means stop and call your provider. This guide is about understanding your body on a peptide: the common symptoms, where your limits are, and when to reach out.Read article ). Unusual thirst, frequent urination or blurred vision are symptoms to report.

IGF-1 and Cancer: What Is Known

The cancer question gets answered online with more confidence than the evidence allows. No study has reported CJC-1295 causing or accelerating cancer in people, and none could have: the published human exposure is small groups of healthy adults for at most 49 days, and no carcinogenicity study exists for any form. Two findings keep the question open. The first is population data: a 2004 Lancet meta-analysis of 21 studies, 3,609 cancer cases and 7,137 controls, found higher odds of prostate cancer (odds ratio 1.49, 75th versus 25th percentile of IGF-1) and premenopausal breast cancer (1.65) with high circulating IGF-1, associations the authors called modest and variable by site. Those are natural IGF-1 levels, not IGF-1 raised by a peptide.

Renehan AG, Zwahlen M, Minder C, et al. "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis." The Lancet. 2004;363(9418):1346-1353. PMID 15110491. View study

The second is laboratory. FDA pharmacologists reported DNA damage in pituitary cells from the DAC form in test-tube and animal experiments, found no two-year carcinogenicity studies of any form, and concluded that pituitary overgrowth and tumors from long-term overstimulation "cannot be ruled out." That is a flag over a gap, not a finding in people. The human evidence on growth hormone secretagogues and cancer is absent rather than reassuring.

Long-Term Side Effects: The Honest Unknown

Searches for CJC-1295 long-term side effects deserve a plain answer: nobody knows, because nobody has looked. The longest published exposure to any form is 49 days, and FDA reviewers wrote that the substances were nominated for a chronic condition "but their long-term safety profile in humans is unknown." The no-DAC form has been sold since around 2010 without a registry, a follow-up study or, in the FDA search of its adverse event database, a usable report: a record of not counting, not a record of safety.

Two long-run questions stand out: the pituitary question above, and antibodies, which can form over months, blunt a peptide’s effect, and at worst cross-react with the body’s own GHRH. Teichman found none of significance after one to three doses, the FDA noted the assay was never described, and nobody has measured it since. The three months on, one month off instruction on the PeRx label is a precaution built around that gap, not a schedule derived from evidence: it caps exposure, gives a natural point to ask your own doctor to recheck IGF-1 and glucose, and shows which effects resolve when the peptide stops (long-term peptide safety Read nextAre Peptides Safe Long-Term? What the Data SaysMost safety questions about peptides assume the timeframe is one or two cycles. The harder question is what happens after a year, three years, or a decade. The honest answer is that peptides fall into three buckets: ones with multi-decade clinical data, ones with several years of safety record but limited long-term studies, and ones where the long-term picture is genuinely incomplete. Here is the bucket each peptide is in and what monitoring matters.Read article ).

Who Gets Screened Out

A licensed provider reviews your health history before anything is compounded (what providers review before prescribing peptides Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.Read article ). For this blend the deciding questions follow the uncertainties above.

When to Stop and Contact a Clinician

The prescribing instructions draw the line in two places.

CJC-1295 Side Effects: Common Questions

Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International Journal of Colorectal Disease. 2014;29(12):1527-1534. PMID 25331030. Intravenous, surgical patients. View study